Versant Venture Capital VI, L.P. 13D and 13G filings for LENZ Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-07-14 4:50 pm Sale |
2025-07-10 | 13D | LENZ Therapeutics, Inc. LENZ |
Versant Venture Capital VI, L.P. | 1,575,899 5.600% |
-391,376 (-19.89%) |
Filing |
| 2025-06-24 4:21 pm Sale |
2025-06-20 | 13D | LENZ Therapeutics, Inc. LENZ |
Versant Venture Capital VI, L.P. | 1,967,275 7.000% |
-133,924 (-6.37%) |
Filing |
| 2025-06-12 4:49 pm Unchanged |
2025-06-10 | 13D | LENZ Therapeutics, Inc. LENZ |
Versant Venture Capital VI, L.P. | 2,101,199 7.500% |
0 (Unchanged) |
Filing |
| 2024-11-08 5:08 pm Unchanged |
2024-08-14 | 13D | LENZ Therapeutics, Inc. LENZ |
Versant Venture Capital VI, L.P. | 2,101,199 7.600% |
0 (Unchanged) |
Filing |
| 2024-03-25 4:43 pm Purchase |
2024-03-21 | 13D | LENZ Therapeutics, Inc. LENZ |
Versant Venture Capital VI, L.P. | 2,101,199 8.200% |
2,101,199 (New Position) |
Filing |